New York, February 6, 2026, 07:50 ET — Premarket
- KVUE shares up 0.2% before the open; stock closed Thursday at $18.07
- Kenvue set Feb. 17 for results release and said it will not hold the usual earnings call
- Investors focus on deal timing and litigation overhang as the Kimberly-Clark transaction moves forward
Kenvue shares edged up in premarket trading on Friday after the consumer health company flagged a Feb. 17 results release and said it will skip the usual quarterly conference call because of its pending transaction with Kimberly-Clark.
The no-call decision matters now because the earnings call is normally when executives field analysts’ questions, and that back-and-forth often moves the stock. Without it, investors will be left with a press release and filings for any fresh detail on performance and the deal.
Kenvue closed up 0.3% on Thursday at $18.07, after trading between $17.82 and $18.22. Volume ran to about 108.8 million shares, far above what the stock typically does on a quiet day.
Kenvue said it will report fourth-quarter and full-year 2025 results after market close on Feb. 17. The company said the press release will be posted on its investor site, and it will not host a quarterly conference call because of the pending Kimberly-Clark transaction.
Kimberly-Clark and Kenvue shareholders voted in late January to approve the acquisition, and the companies said they expect to close in the second half of 2026, subject to regulatory approvals and other customary conditions. Kimberly-Clark CEO Mike Hsu called the vote a milestone that “advances our efforts to create a preeminent global health and wellness leader,” while Kenvue CEO Kirk Perry said Kenvue “remain[s] confident in the growth opportunities ahead for the combined company.” Kenvue
A merger filing shows each Kenvue share is set to convert into 0.14625 shares of Kimberly-Clark stock plus $3.50 in cash. Using Kimberly-Clark’s latest premarket price of $104.26, that implies roughly $18.75 per Kenvue share, leaving Kenvue trading about 70 cents below the headline consideration.
Kenvue sells brands including Tylenol, Listerine, Band-Aid and Neutrogena. Johnson & Johnson spun the business off in 2023.
For the next session, traders will likely watch Kimberly-Clark shares closely because the offer includes a stock component, which can move the implied value day to day. The other near-term focus is whether the company offers any additional written disclosure alongside the Feb. 17 release, with no Q&A planned.
But the downside scenario is still there. The deal needs regulatory sign-offs, and investors have also pointed to product litigation risk — including cases tied to talc-based baby powder — as a source of uncertainty around timing and valuation.
